Matthew J O'Neill,Chai-Ann Ng,Takanori Aizawa,Luca Sala,Sahej Bains,Annika Winbo,Rizwan Ullah,Qianyi Shen,Chek-Ying Tan,Krystian Kozek,Loren R Vanags,Devyn W Mitchell,Alex Shen,Yuko Wada,Asami Kashiwa,Lia Crotti,Federica Dagradi,Giulia Musu,Carla Spazzolini,Raquel Neves,J Martijn Bos,John R Giudicessi,Xavier Bledsoe,Eric R Gamazon,Megan C Lancaster,Andrew M Glazer,Bjorn C Knollmann,Dan M Roden,Jochen Weile,Frederick Roth,Joe-Elie Salem,Nikki Earle,Rachael Stiles,Taylor Agee,Christopher N Johnson,Minoru Horie,Jonathan Skinner,Michael J Ackerman,Peter J Schwartz,Seiko Ohno,Jamie I Vandenberg,Brett M Kroncke

Abstract:Background: Long QT syndrome is a lethal arrhythmia syndrome, frequently caused by rare loss-of-function variants in the potassium channel encoded by KCNH2. Variant classification is difficult, often because of lack of functional data. Moreover, variant-based risk stratification is also complicated by heterogenous clinical data and incomplete penetrance. Here we sought to test whether variant-specific information, primarily from high-throughput functional assays, could improve both classification and cardiac event risk stratification in a large, harmonized cohort of KCNH2 missense variant heterozygotes. Methods: We quantified cell-surface trafficking of 18 796 variants in KCNH2 using a multiplexed assay of variant effect (MAVE). We recorded KCNH2 current density for 533 variants by automated patch clamping. We calibrated the strength of evidence of MAVE data according to ClinGen guidelines. We deeply phenotyped 1458 patients with KCNH2 missense variants, including QTc, cardiac event history, and mortality. We correlated variant functional data and Bayesian long QT syndrome penetrance estimates with cohort phenotypes and assessed hazard ratios for cardiac events. Results: Variant MAVE trafficking scores and automated patch clamping peak tail currents were highly correlated (Spearman rank-order ρ=0.69; n=433). The MAVE data were found to provide up to pathogenic very strong evidence for severe loss-of-function variants. In the cohort, both functional assays and Bayesian long QT syndrome penetrance estimates were significantly predictive of cardiac events when independently modeled with patient sex and adjusted QT interval (QTc); however, MAVE data became nonsignificant when peak tail current and penetrance estimates were also available. The area under the receiver operator characteristic curve for 20-year event outcomes based on patient-specific sex and QTc (area under the curve, 0.80 [0.76-0.83]) was improved with prospectively available penetrance scores conditioned on MAVE (area under the curve, 0.86 [0.83-0.89]) or attainable automated patch clamping peak tail current data (area under the curve, 0.84 [0.81-0.88]). Conclusions: High-throughput KCNH2 variant MAVE data meaningfully contribute to variant classification at scale, whereas long QT syndrome penetrance estimates and automated patch clamping peak tail current measurements meaningfully contribute to risk stratification of cardiac events in patients with heterozygous KCNH2 missense variants.

Clinical interpretation of KCNH2 variants using a robust PS3/BS3 functional patch-clamp assay

Assays of Variant Effect and Automated Patch Clamping Improve KCNH2-LQTS Variant Classification and Cardiac Event Risk Stratification

Prognostic Value of Multiplexed Assays of Variant Effect and Automated Patch-clamping for KCNH2-LQTS Risk Stratification

Clinical Aspects of Type-1 Long-Qt Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene.

Identification of A Kir3.4 Mutation in Congenital Long Qt Syndrome

Abstract Sa906: Topological Distribution of KCNH2 Variants and Genotype-Phenotype Relationship in Patients with Long QT Syndrome

Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome.

Abstract 16901: Utilizing in Silico Pathogenicity Prediction Tools and Heterologous Expression Patch Clamp Studies to Identify Bona Fide Pathogenic KCNH2 Variants among Publically Available Exomes Derived from Subjects Without Evidence for Either Type 2 Long QT Syndrome or Type 1 Short QT Syndrome

Novel Compound Heterozygous Mutations in the KCNQ1 Gene Associated with Autosomal Recessive Long QT Syndrome (jervell and Lange‐Nielsen Syndrome)

Utilization of the Genome Aggregation Database, in Silico Tools, and Heterologous Expression Patch Clamp Studies to Identify and Demote Previously Published Type 2 Long QT Syndrome-Causative Variants from Pathogenic to Likely Benign.

Mutations in conserved amino acids in the KCNQ1 channel and risk of cardiac events in type-1 long-QT syndrome.

Denaturing High-Performance Liquid Chromatography Quickly And Reliably Detects Cardiac Ion Channel Mutations In Long Qt Syndrome

Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations

Association of Ion Channel Genes KCNQ1 and KCNH2 with Congenital Long-QT Syndrome

Mutations In Cytoplasmic Loops Of The Kcnq1 Channel And The Risk Of Life-Threatening Events Implications For Mutation-Specific Response To Beta-Blocker Therapy In Type 1 Long-Qt Syndrome

A Phenotype-Enhanced Variant Classification Framework to Decrease the Burden of Missense Variants of Uncertain Significance in Type 1 Long QT Syndrome

Characterization Of A Kcnq1/Kvlqt1 Polymorphism In Asian Families With Lqt2: Implications For Genetic Testing

High-throughput Evaluation of Epilepsy-associated KCNQ2 Variants Reveals Functional and Pharmacological Heterogeneity

Genetic characterization of KCNQ1 variants improves risk stratification in type 1 long QT syndrome patients

Mutation-Specific Risk in Two Genetic Forms of Type 3 Long QT Syndrome

Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events